Objective: To investigate the impact of socioeconomic status-related parameters on competing (non-bladder cancer) mortality after radical cystectomy. Patients and Methods: A total of 1,268 consecutive patients who underwent radical cystectomy for urothelial or undifferentiated bladder cancer at our institution between 1993 and 2016 with a mean age of 69 years (median 70 years) were studied. The mean -follow-up of the censored patients was 7.2 years (median 5.7 years). Proportional hazard models for competing risk were used to identify predictors of non-bladder cancer (competing) mortality. The following parameters were included into multivariate analyses: age, American Society of Anesthesiologists physical status classification, Charlson score, gender, level of education, smoking status, marital status, local tumour stage, lymph node status, adjuvant and neoadjuvant chemotherapy. Results: Besides age and both comorbidity classifications, the socioeconomic status-related parameters gender (female versus male, hazard ratio [HR] 0.58, 95% CI 0.40–0.84, p = 0.0042), level of education (university degree or master craftsman versus others, HR 0.76, 95% CI 0.56–0.1.03, p = 0.0801), smoking status (current smoking versus others, HR 1.47, 95% CI 1.10–1.96, p = 0.0085) and marital status (married versus others, HR 0.68, 95% CI 0.50–0.92, p = 0.0133) were independent predictors of competing mortality after radical cystectomy. If considered in combination (multiplication of HRs), the prognostic impact of socioeconomic parameters superseded that of the investigated comorbidity classifications. Conclusion: Socioeconomic status-related parameters may provide important information on the long-term competing mortality risk after radical cystectomy supplementary to chronological age and comorbidity.

Keywords:
Bladder, Comorbidity, Competing mortality, Competing risk analysis, Cystectomy, Proportional hazards model, Socioeconomic
1.
Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, et al. Systematic review of comorbidity and competing-risks assessments for bladder cancer patients.
Eur Urol Oncol
. 2018 Jun;1(2):91–100.
2.
Gierth M, Zeman F, Denzinger S, Vetterlein MW, Fisch M, Bastian PJ, et al. Influence of body mass index on clinical outcome parameters, complication rate and survival after radical cystectomy: evidence from a prospective European multicentre study.
Urol Int
. 2018;101(1):16–24.
3.
Cerruto MA, D’Elia C, Siracusano S, Saleh O, Gacci M, Cacciamani G, et al. Health-related quality of life after radical cystectomy for bladder cancer in elderly patients with ileal orthotopic neobladder or ileal conduit: results from a multicentre cross-sectional study using validated questionnaires.
Urol Int
. 2018;100(3):346–52.
4.
Begum G, Dunn JA, Bryan RT, Bathers S, Wallace DM; West Midlands Urological Research Group. Socio-economic deprivation and survival in bladder cancer.
BJU Int
. 2004 Sep;94(4):539–43.
5.
Odisho AY, Etzioni R, Gore JL. Beyond classic risk adjustment: socioeconomic status and hospital performance in urologic oncology surgery.
Cancer
. 2018 Aug;124(16):3372–80.
6.
Shackley DC, Clarke NW. Impact of socioeconomic status on bladder cancer outcome.
Curr Opin Urol
. 2005 Sep;15(5):328–31.
7.
American Society of Anesthesiologists. American Society of Anesthesiologists physical status classification system (accessed ­February 20, 2019). Available from: http://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system.
8.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
. 1987;40(5):373–83.
9.
Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B, et al. Curative treatment for muscle invasive bladder cancer in elderly patients: A systematic review.
Eur Urol
. 2018 Jan;73(1):40–50.
10.
Klapheke A, Yap SA, Pan K, Cress RD. Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.
Urol Oncol
. 2018 Jun;36(6):308.e19–25.
11.
Weiner AB, Keeter MK, Manjunath A, Meeks JJ. Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013).
Urol Oncol
. 2018 May;36(5):237.e9–17.
12.
Golombos DM, O’Malley P, Lewicki P, Nguyen DP, Stone BV, Al Hussein Al Awamlh B, et al. The impact of socioeconomic status on perioperative complications and oncologic outcomes in patients undergoing radical cystectomy.
World J Urol
. 2017 Jul;35(7):1063–71.
13.
Datta GD, Neville BA, Kawachi I, Datta NS, Earle CC. Marital status and survival following bladder cancer.
J Epidemiol Community Health
. 2009 Oct;63(10):807–13.
14.
Gore JL, Kwan L, Saigal CS, Litwin MS. Marriage and mortality in bladder carcinoma.
Cancer
. 2005 Sep;104(6):1188–94.
15.
Sammon JD, Morgan M, Djahangirian O, Trinh QD, Sun M, Ghani KR, et al. Marital status: a gender-independent risk factor for poorer survival after radical cystectomy.
BJU Int
. 2012 Nov;110(9):1301–9.
16.
Smith ND, Prasad SM, Patel AR, Weiner AB, Pariser JJ, Razmaria A, et al. Bladder cancer mortality in the United States: A geographic and temporal analysis of socioeconomic and environmental factors.
J Urol
. 2016 Feb;195(2):290–6.
17.
Pakzad R, Mohammadian-Hafshejani A, Mohammadian M, Pakzad I, Safiri S, Khazaei S, et al. Incidence and mortality of bladder cancer and their relationship with development in Asia.
Asian Pac J Cancer Prev
. 2015;16(16):7365–74.
18.
Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer.
Eur Urol
. 2017 Mar;71(3):462–75.
19.
Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, et al. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.
J Urol
. 2013 Jul;190(1):55–60.
20.
Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline (accessed February 20, 2019). Available from: https://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasive-(2017).
21.
Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, et al. ­Defining a standard set of patient-centered outcomes for men with localized ­prostate cancer.
Eur Urol
. 2015 Mar;67(3):460–7.
22.
Robinski M, Strich F, Mau W, Girndt M. Validating a patient-reported comorbidity measure with respect to quality of life in end-stage renal disease.
PLoS One
. 2016 Jun;11(6):e0157506.
23.
Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research.
Arthritis Rheum
. 2003 Apr;49(2):156–63.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.